Showing results (141-150 of 156) with videos related to
Sort By:
Pageof 16
ESMO Open|April 3, 2020
Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania 'Luigi Vanvitelli'Vincenzo De Falco, Luca Poliero, Pietro Paolo Vitello, et al.Lung Cancer (Amsterdam, Netherlands)|June 16, 2019
Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trialsAlessandro Morabito, Maria Carmela Piccirillo, Paolo Maione, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2012
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trialCesare Gridelli, Fortunato Ciardiello, Ciro Gallo, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 17, 2012
Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancerMassimo Di Maio, Natasha B Leighl, Ciro Gallo, et al.Journal of Clinical Medicine|May 14, 2025
Cardio-Oncology Challenges in Elderly PatientsEster Topa, Eliana De Rosa, Alessandra Cuomo, et al.European Journal of Cancer (Oxford, England : 1990)|August 21, 2020
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancerClaudia Cardone, Bernadette Blauensteiner, Veronica Moreno-Viedma, et al.Iscience|March 4, 2025
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancerCaterina De Rosa, Floriana Morgillo, Luisa Amato, et al.European Journal of Cancer (Oxford, England : 1990)|November 11, 2022
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysisGiuseppe Viscardi, Antonino C Tralongo, Francesco Massari, et al.Cancer Immunology, Immunotherapy : CII|July 12, 2025
Real-world effectiveness and safety of first-line chemoimmunotherapy combinations in metastatic non-small cell lung cancer with programmed death ligand-1 < 50%: results from an Italian observational studyAlessandro Inno, Antonello Veccia, Ettore D'Argento, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 6, 2022
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 TrialMaria Carmela Piccirillo, Laura Bonanno, Marina Chiara Garassino, et al.Pageof 16